A Phase III, Multicenter, Prospective, Randomized, Controlled Clinical Trial Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer (TOP-GC)
This is a phase III, multicenter, prospective, randomized, controlled clinical trial to evaluate the impact of omentectomy for advanced gastric cancer on patient survival.
• Had been treated with Radical resection (D2, R0) of gastric cancer (Lymph node≥16);
• Physical condition and organ function allows to tolerable abdominal surgery;
• Willing and able to comply with the program during the study period;
• Written informed consent provided;
• ≥ 18 and ≤ 70 years of age; preoperative gastric cancer patients with pathologically confirmed;
• With more than a 6-month life expectancy;
• No other serious concomitant diseases; Sufficient organ functions;
• No previous history of chemotherapy or radiotherapy;
• All patients accept 8 cycles XELOX chemotherapy regimen;
⁃ Clinical stage: T3-4aN0-+M0; 11 . Macroscopic types :Borrmann I-III;
‣ 12\. Not greater curvature tumor; with distal or total gastrectomy； 13. No previous surgery for any abdominal disease, except an appendectomy for appendicitis, a laparoscopic cholecystectomy for gallbladder stones; No previous history of peritonitis, pancreatitis; 14. Karnofsky performance status (KPS)\>60; Eastern Cooperative Oncology Group Performance Status (ECOG): 0-1.